Belite Bio

Rank#2473

Market Cap7.80B

CountryUnited States

Summary

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

History

Belite Bio was founded in 2020 with a vision to deliver novel and meaningful breakthroughs in the area of biotechnology. The company has grown from a small startup to a leading biotechnology company, with a mission of improving outcomes for patients and creating innovative solutions for unmet medical needs.

Mission

Belite Bio is committed to developing therapeutic treatments for complex diseases that improve people’s lives.

Vision

Belite Bio’s vision is to be a leading biotechnology company that is determined to find and bring innovative solutions to the world.

References

https://in.investing.com/equities/belite-bio-adr

https://www.comparably.com/companies/vision/mission

https://www.crunchbase.com/organization/belite-bio

https://finance.yahoo.com/quote/BLTE/

https://belitebio.com

https://sec.report/CIK/0001889109

Leadership team